On the basis of our experience, we would suggest that control of HIV-RNA viremia in liver transplanted patients is still a matter of the choice of the best ART independently from the type of the antirejection treatment; moreover, the use of rapamycin in this context may bemisleading because it has been already clearly demonstrated that ART has an impact on overall survival in HIV-positive liver transplanted patients.
mTOR immunosuppression in HIV-positive liver transplant recipients
GROSSI, PAOLO ANTONIO;
2010-01-01
Abstract
On the basis of our experience, we would suggest that control of HIV-RNA viremia in liver transplanted patients is still a matter of the choice of the best ART independently from the type of the antirejection treatment; moreover, the use of rapamycin in this context may bemisleading because it has been already clearly demonstrated that ART has an impact on overall survival in HIV-positive liver transplanted patients.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
mTOR immunosuppression il HIV-positive liver transplant recipients.pdf
non disponibili
Tipologia:
Documento in Post-print
Licenza:
DRM non definito
Dimensione
82.37 kB
Formato
Adobe PDF
|
82.37 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
